Medicines
Discover all available medicines and treatments
Discover all available medicines and treatments
Brand: Zontivity
Vorapaxar is an antiplatelet drug that works by inhibiting protease-activated receptor-1 (PAR-1), a thrombin receptor on platelets. This prevents thrombin from activating platelets, thereby reducing platelet aggregation and the risk of thrombosis. It is primarily used in patients with a history of myocardial infarction or peripheral artery disease.
For reducing the risk of cardiovascular events in patients with a history of myocardial infarction or peripheral artery disease.
Increased risk of bleeding, including intracranial hemorrhage. Use with caution in patients at high risk of bleeding.
Outcome:
Increased bleeding risk
Mechanism:
Additive antiplatelet effects
Outcome:
Increased vorapaxar levels
Mechanism:
Inhibition of CYP3A4 metabolism
Outcome:
Slightly decreased vorapaxar absorption
Mechanism:
Changes in gastric pH
Most likely new formulation: Extended-release formulation (Year: 2026, 70% confidence)
Based on current usage and safety profile, there is a low probability (<5%) of regulatory restrictions in the next 5 years.
Antiplatelet Agent
Pyrrolopyrimidine